188 related articles for article (PubMed ID: 35233640)
1. Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.
den Hollander D; Dirkson AR; Verberne S; Kraaij W; van Oortmerssen G; Gelderblom H; Oosten A; Reyners AKL; Steeghs N; van der Graaf WTA; Desar IME; Husson O
Support Care Cancer; 2022 Jun; 30(6):5137-5146. PubMed ID: 35233640
[TBL] [Abstract][Full Text] [Related]
2. Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa).
Eichler M; Pink D; Menge F; Jakob J; Hentschel L; Richter S; Hohenberger P; Kasper B; Andreou D; Singer S; Grützmann R; Dmytrow DI; Arndt K; Tuchscherer A; Reichardt P; Ahrens M; Kunitz A; Mohm J; Bornhäuser M; Schmitt J; Schuler MK
Eur J Cancer Care (Engl); 2021 Nov; 30(6):e13484. PubMed ID: 34342924
[TBL] [Abstract][Full Text] [Related]
3. Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor.
Chae H; Ryu MH; Ma J; Beck M; Kang YK
Invest New Drugs; 2020 Apr; 38(2):493-499. PubMed ID: 31628586
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H; Jones RL; Blay JY; George S; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Harrow B; Becker C; Reichmann W; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S;
Eur J Cancer; 2023 Oct; 192():113245. PubMed ID: 37598656
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors.
Poort H; van der Graaf WT; Tielen R; Vlenterie M; Custers JA; Prins JB; Verhagen CA; Gielissen MF; Knoop H
J Pain Symptom Manage; 2016 Aug; 52(2):265-71. PubMed ID: 27233141
[TBL] [Abstract][Full Text] [Related]
7. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
[TBL] [Abstract][Full Text] [Related]
8. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
Wang Y; Zhang P; Han Y; Nelson RS; McLeod HL; Tao K; Yuan Y; Zhang M; Xiang H; Zhou H
Chemotherapy; 2019; 64(4):197-204. PubMed ID: 31955170
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.
Sodergren SC; White A; Efficace F; Sprangers M; Fitzsimmons D; Bottomley A; Johnson CD
Crit Rev Oncol Hematol; 2014 Jul; 91(1):35-46. PubMed ID: 24495942
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
12. Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?
Custers JA; Tielen R; Prins JB; de Wilt JH; Gielissen MF; van der Graaf WT
Acta Oncol; 2015; 54(8):1202-8. PubMed ID: 25734906
[TBL] [Abstract][Full Text] [Related]
13. Self-reported cognitive impairments and quality of life in patients with gastrointestinal stromal tumor: Results of a multinational survey.
Ferguson RJ; Manculich J; Chang H; Sareen NJ; Snitz BE; Terhorst L; Bovbjerg DH; Duensing AU
Cancer; 2022 Nov; 128(22):4017-4026. PubMed ID: 36125989
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature.
van de Wal D; Elie M; Le Cesne A; Fumagalli E; den Hollander D; Jones RL; Marquina G; Steeghs N; van der Graaf WTA; Husson O
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406604
[TBL] [Abstract][Full Text] [Related]
15. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
Ben Ami E; Demetri GD
Expert Opin Drug Saf; 2016; 15(4):571-8. PubMed ID: 26865352
[TBL] [Abstract][Full Text] [Related]
16. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
17. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Le Cesne A; Blay JY; Reichardt P; Joensuu H
Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
[TBL] [Abstract][Full Text] [Related]
18. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
19. Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors.
van Elst JM; IJzerman NS; Mathijssen RHJ; Steeghs N; Reyners AKL; de Haan JJ
Support Care Cancer; 2022 Mar; 30(3):2307-2315. PubMed ID: 34727226
[TBL] [Abstract][Full Text] [Related]
20. [Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
Yu L; Wang HB; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):929-935. PubMed ID: 27995875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
